Structure Therapeutics Prices $650 Million Upsized Public Offering

Written by Emily J. Thompson, Senior Investment Analyst

GPCR+4.26%

Source: Newsfilter

Updated: Dec 10 2025

0mins

Source: Newsfilter

Upsized Offering: Structure Therapeutics announced the pricing of 8,461,538 American depositary shares at $65 each, expecting gross proceeds of approximately $650 million, reflecting strong market demand for its novel oral small molecule therapeutics.
Pre-Funded Warrants: The offering includes 1,538,462 pre-funded warrants priced at $64.9999 each, enhancing investor participation and potentially providing additional funding for the company.
Strong Underwriter Lineup: Notable financial institutions such as Jefferies, Goldman Sachs, and Morgan Stanley are acting as joint book-running managers, boosting market confidence in the transaction and ensuring a smooth completion.
Future Growth Potential: The offering is expected to close on December 11, 2025, with proceeds aimed at supporting the company's R&D in metabolic diseases, further solidifying its competitive position in the biopharmaceutical industry.

GPCR

$88.64+Infinity%1D

Analyst Views on GPCR

Wall Street analysts forecast GPCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 74.00 USD with a low forecast of 50.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Analyst Rating

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 85.020

Low

50.00

Averages

74.00

High

100.00

Current: 85.020

Low

50.00

Averages

74.00

High

100.00

H.C. Wainwright

Ananda Ghosh

Buy

upgrade

$60 -> $90

Al Analysis

2025-12-19

Reason

H.C. Wainwright

Ananda Ghosh

Price Target

$60 -> $90

Al Analysis

2025-12-19

upgrade

Buy

Reason

H.C. Wainwright analyst Ananda Ghosh raised the firm's price target on Structure Therapeutics to $90 from $60 and keeps a Buy rating on the shares. The firm says its key opinion leader feedback validates the company's titration strategy. With oral GLP-1s set to become "Tier 1 therapies" driven by payer economics, Structure's current valuation offers a "massive arbitrage opportunity relative to recent deal metrics with a strong M&A potential," the analyst tells investors in a research note. H.C. Wainwright views the company's recent Phase 2 data as encouraging.

Citi

Samantha Semenkow

Buy

maintain

$60 -> $100

2025-12-09

Reason

Citi

Samantha Semenkow

Price Target

$60 -> $100

2025-12-09

maintain

Buy

Reason

Citi analyst Samantha Semenkow raised the firm's price target on Structure Therapeutics to $100 from $60 and keeps a Buy rating on the shares. The positive Phase 2b data for aleniglipron gives Structure an attractive oral obesity asset, the analyst tells investors in a research note. The firm sees the drug getting "significant interest from strategics" looking to enter the oral obesity market. Citi believes aleniglipron showed "potential best-in-class" weight loss with competitive tolerability.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GPCR

Unlock Now

Morgan Stanley

Terence Flynn

Overweight

maintain

$120

2025-12-08

Reason

Morgan Stanley

Terence Flynn

Price Target

$120

2025-12-08

maintain

Overweight

Reason

After Structure Therapeutics (GPCR) announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity, Morgan Stanley analyst Terence Flynn argues that 36-week data from the core Phase 2b ACCESS study "appear competitive" with Eli Lilly's (LLY) orforglipron. The firm, which models an aleniglipron U.S. launch in 2028 and 2040 worldwide unadjusted sales of $6.3B, has an Overweight rating and $120 price target on Structure shares.

H.C. Wainwright

maintain

$60

2025-12-08

Reason

H.C. Wainwright

Price Target

$60

2025-12-08

maintain

Reason

After Structure Therapeutics (GPCR) released pivotal topline data from the Phase 2b ACCESS program, H.C. Wainwright argues that the clean safety profile along with 15.3% placebo-adjusted weight loss at the 240 mg dose shatters the "oral ceiling," exceeding the roughly 12.4% efficacy benchmark set by Eli Lilly's (LLY) orforglipron. The firm, which sees the data validating the "bull case" thesis the firm previously outlined, has a Buy rating and $60 price target on Structure shares.

About GPCR

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.